Opella Helskea

History

2022: Recall of the drug "Phosphalyugel" in Russia due to exceeding the permissible lead norm

In March 2022, the Federal Service for Supervision of Health Care (Roszdravnadzor) on the basis of announced the decision of Opella Helskea France SAS ( included in the Sanofi group), which is the holder of registration certificate P N012655/01 from the 05.03.2009 for drugs with the trade name "Phosphalugel," to withdraw from circulation some series of drugs due to the detection in them of excess of the permissible daily lead content. We are talking about the drug "Phosphalugel, gel for ingestion 16 g, sachets (20), cardboard packs." More details here.

2020: Sanofi created Opella Helskea in Russia

As it became known in early October 2020, the Russian representative office of the French pharmaceutical company Sanofi created a new trading company in the Russian Federation - Opella Helskea LLC. This is evidenced by the data of the Unified State Register of Legal Entities.

Irina Romanova, former general manager of Sanofi Eurasia, was appointed general director of Opella Helskea. The new company will be engaged in the wholesale trade of pharmaceutical products. An additional area of ​ ​ activity relates to agents specializing in the wholesale trade in pharmaceutical products, medical products, perfume and cosmetic products, including soap, and cleaning products.

Sanofi created Opella Helskea wholesale company in Russia

As part of Sanofi's "Play to Win" strategy, announced in December 2019, the business unit of over-the-counter drugs and health products should become an independent global organization. This decision is aimed at ensuring that over-the-counter business grows faster than the market. Among the various initiatives implemented in this context, a separate legal entity was registered under the name Opella Helskea LLC, "Yuri Mochalin, director of external relations at Sanofi in the Eurasian region, told Vademecum.

The creation of Sanofi a new company in Russia became known about a month and a half after the pharmacigant registered in the Russian Federation the drug "Frisium" (also known as klobazam), used to combat epilepsy in children. The certificate is issued for five years. Earlier, the drug, which in Russia belongs to psychotropic, was not registered in the country, because of which criminal cases were instituted against citizens who transported it to the Russian Federation for sick children. Klobazam turnover in the Russian Federation is limited. Its registration expired in 1997, the manufacturer initially did not plan to renew it.^[1]

Notes